undamentalytics Newsletter
Sign in

Aveanna Healthcare Holdings, Inc. (AVAH) stock

Add to watchlist

Add holding +

NASDAQ: AVAH Nasdaq Health Care Services Next results ~November 12, 2026

C+ Fundamentals grade

Aveanna Healthcare Holdings, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: after-tax interest is 95% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Price vs value

Under review: after-tax interest is 95% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.

Aveanna Healthcare Holdings, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 9 selling0 purchases and 71 sales by directors and officers, last 12 monthsInsider trades
  • Funds149 adding, 82 cuttingOf 56 active managers that changed their stake, 32 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Aveanna Healthcare Holdings files

Where Aveanna Healthcare stands after its latest 10-Q

Revenue for the twelve months to July 2026 was $2.60bn, up 19.5% on a year earlier, slower than the 20.5% growth a quarter earlier. Free-cash-flow margin rose to 6.0% from 3.5% a year earlier. The diluted share count is up 11.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 1 of our 7 financial-health checks.

Our model value for Aveanna Healthcare Holdings is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Aveanna Healthcare Holdings, Inc.'s trailing-twelve-month revenue grew 19.5% year on year, with a free-cash-flow margin of 6.0%. Where it stands out: net margin of 10.6% ranks 6 of 41 health care services companies we cover. Where it lags: long-term debt as % of assets of 61.0% ranks 29 of 31 health care services companies we cover.

Our discounted-cash-flow model values the business at ~$25 per share in the base case (~$17–$34 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 107.9% while net income grew 1380.8%: a 1273pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 19.5% over the last 12 months, against a median of 7.3% for health care services companies we cover.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 16.9% over 90 days.

Things to watch

  • Share dilution. Diluted shares rose 11.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 48% and a beta of 0.6 against the S&P 500.
  • Insiders selling. 9 insiders sold $782M of stock over the past 365 days and none bought (1% under pre-set trading plans).
  • Weak cash conversion. Free cash flow was 57% of net income over the last 12 months.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 61.0% ranks 29 of 31 health care services companies we cover (median 27.7%).
  • Below peers: change in growth rate. Change in growth rate of -1.0pp ranks 31 of 41 health care services companies we cover (median +1.1pp).

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
$0.22 against an average estimate of $0.17: beat by 31.6%
Revenue
$670m, up 13.7% on a year earlier
Share reaction
+36.1% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Guidance given
revenue $2.68bn (full fiscal year 2026); adjusted EBITDA $365m (full fiscal year 2026)
Next report
November 12, 2026; average EPS estimate $0.21

Aveanna Healthcare Holdings' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.3%
  • 1 week-0.5%
  • 1 month+4.2%
  • This year+60.6%
  • 1 year+45.0%
  • 5 years+56.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.6B
Operating margin
10.5%
Net margin
10.6%
EPS (TTM, diluted)
$1.23

Growth

Revenue growth
+19.5%
Change in growth rate
−1.0 pts
Share count change
+11.4%

Cash

Free cash flow (TTM)
$157M
FCF margin
6.0%
Stock pay % of revenue
0.7%

Earnings

Last results
August 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Announcement
  3. Insider trade
  4. Insider trade
  5. Insider trade
  6. Insider trade
  7. Insider trade
  8. Insider trade
  9. Insider trade
  10. Insider trade
  11. Announcement
  12. Results
  13. Guidance
  14. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Aveanna Healthcare Holdings, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: after-tax interest is 95% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Aveanna Healthcare Holdings, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.03 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$16 ~$14–$25 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Aveanna Healthcare Holdings, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$7.40$0.78$2.68$4.66$8.08$13.12
Market value$1.3bn$145m$509m$899m$1.7bn$2.9bn
+ Net debt (− = net cash)$1.2bn$1.3bn$1.3bn$1.2bn$1.1bn$1.2bn
Enterprise value$2.5bn$1.4bn$1.8bn$2.1bn$2.9bn$4.1bn
Multiples
Price / sales 0.8x0.1x0.3x0.4x0.7x1.1x
Price / earnings ————7.7x10.6x
Price / free cash flow ——22.5x27.5x13.8x17.4x
EV / EBITDA ——81.5x14.1x10.7x14.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

18 /100

Weak moat

How hard Aveanna Healthcare Holdings's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -4.0% of total assets over 6 years.

  • Pricing power 12 / 20

    Gross margin has been a median 31.9%, moving by 0.9 percentage points (standard deviation) across 6 years.

  • Durability 0 / 20

    Operating margin has been a median 3.0%; its worst year was -31.3%.

  • Cash conversion 7 / 20

    Free cash flow was positive in 4 of 6 years, at a median 0.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (23 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $681m and EPS of $0.21 (range $0.19 to $0.23) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.82 +37% $2.7bn +11%
Next $0.91 +10% $2.9bn +8%

Next year's EPS estimate has moved +16.9% in 90 days, across 11 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +16.6% on 90 days ago. In the last 30 days, 1 analyst raised Aveanna Healthcare Holdings, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Aveanna Healthcare Holdings, Inc., last 90 days
$0.70 $0.80 $0.90 $1.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.71 Current fiscal year, 60 days ago: $0.83 Current fiscal year, 30 days ago: $0.82 Current fiscal year, 7 days ago: $0.82 Current fiscal year, Now: $0.82 $0.82 Next fiscal year, 90 days ago: $0.78 Next fiscal year, 60 days ago: $0.88 Next fiscal year, 30 days ago: $0.91 Next fiscal year, 7 days ago: $0.91 Next fiscal year, Now: $0.91 $0.91

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.71$0.78
60 days ago $0.83$0.88
30 days ago $0.82$0.91
7 days ago $0.82$0.91
Now $0.82$0.91

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.17 $0.22 +31.6%
Mar 2026 $0.13 $0.18 +41.9%
Dec 2025 $0.16 $0.17 +8.7%
Sept 2025 $0.13 $0.15 +14.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 13, 2026
  • Revenue full fiscal year 2026 about $2.68bn Raised
    “Revenue of greater than $2.68 billion, updated from between $2.63 and $2.65 billion.” source
  • Adjusted EBITDA full fiscal year 2026 about $365m Non-GAAP Raised
    “Adjusted EBITDA of greater than $365 million, updated from between $338 and $342 million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

11 analysts, Nov 2026
Buy873%
Hold327%
Sell00%

Monthly trend

  1. Nov 202626311
  2. Oct 202626311
  3. Sep 202626311

Counts of recommendations published by analysts covering Aveanna Healthcare Holdings, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.9%
of tradable shares
Days to cover
1.72
at average volume
Short interest, 1 month
−3%
to October 15, 2026
Held by institutions
94%
of shares
Held by insiders
5.6%
of shares
Employees
3,500
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +45.0%

$9.05 on October 31, 2025 to $13.12

ThenNowEffect
Revenue (last 12 months) $2.2bn $2.6bn +19.5%
Net margin 0.9% 10.6% +1138.9%
P/E multiple 97.4x 10.6x −89.1%
Share count 200m 223m −10.2%

Biggest factor: net margin.

Last 3 years +792.5%

$1.47 on November 3, 2023 to $13.12

ThenNowEffect
Revenue (last 12 months) $1.8bn $2.6bn +42.0%
P/S multiple 0.2x 1.1x +645.2%
Share count 188m 223m −15.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
AVAH−90%+244%+71%+79%+61%
Industry peers (median)−25%+6%−6%−9%+15%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
AVAH17%50%58%58%64%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
AVAH−91%−41%−28%−38%−36%
S&P 500−25%−10%−8%−19%−9%

Worst fall since April 28, 2021: 95% from June 14, 2021 to December 29, 2022. Getting back needed a 1807% gain, reached on August 19, 2026, 1329 days after the low.

Price behaviour

52-week range
$6.22 – $14.38
From 52-week high
−8.8%
vs 50-day average
+0.1%
vs 200-day average
+41.9%
Volatility (1 year)
48%
Beta vs S&P 500
0.60

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
9 up, 3 down
typical move ±21.1%
After a week
9 up, 3 down
typical move ±25.3%
After a month
8 up, 4 down
typical move ±25.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 +36.1% +0.5% +43.3% +58.9%
May 14, 2026 +14.0% −0.4% +13.3% +6.8%
March 19, 2026 −5.6% −1.7% −4.3% −0.6%
January 14, 2026 +15.0% −0.2% +5.1% −6.6%
November 6, 2025 −5.0% −1.0% −7.3% −0.1%
October 21, 2025 −7.7% −0.5% −4.5% −17.7%
August 7, 2025 +57.8% +0.7% +85.1% +112.3%
May 8, 2025 +12.0% +0.6% +24.5% +13.5%
March 13, 2025 +38.8% +0.7% +46.0% +20.1%
November 7, 2024 +21.2% +1.2% +14.6% +8.9%
August 8, 2024 +37.3% +2.8% +45.8% +59.8%
May 9, 2024 +3.3% +0.7% +9.5% +3.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Aveanna Healthcare Holdings, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Aveanna Healthcare Holdings, Inc.
$1.8B $2B $2.2B $2.4B $2.6B $2.8B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.9B Revenue (TTM), FY23 Q4: $1.9B Revenue (TTM), FY24 Q1: $1.9B Revenue (TTM), FY24 Q2: $2B Revenue (TTM), FY24 Q3: $2B Revenue (TTM), FY24 Q4: $2B Revenue (TTM), FY25 Q1: $2.1B Revenue (TTM), FY25 Q2: $2.2B Revenue (TTM), FY25 Q3: $2.3B Revenue (TTM), FY25 Q4: $2.4B Revenue (TTM), FY26 Q1: $2.5B Revenue (TTM), FY26 Q2: $2.6B $2.6B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.9B
FY23 Q4 $1.9B
FY24 Q1 $1.9B
FY24 Q2 $2B
FY24 Q3 $2B
FY24 Q4 $2B
FY25 Q1 $2.1B
FY25 Q2 $2.2B
FY25 Q3 $2.3B
FY25 Q4 $2.4B
FY26 Q1 $2.5B
FY26 Q2 $2.6B
Revenue growth, TTM YoY Aveanna Healthcare Holdings, Inc.
0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 6.7% Revenue growth, TTM YoY, FY23 Q4: 6.0% Revenue growth, TTM YoY, FY24 Q1: 6.4% Revenue growth, TTM YoY, FY24 Q2: 6.5% Revenue growth, TTM YoY, FY24 Q3: 6.2% Revenue growth, TTM YoY, FY24 Q4: 6.8% Revenue growth, TTM YoY, FY25 Q1: 9.0% Revenue growth, TTM YoY, FY25 Q2: 11.5% Revenue growth, TTM YoY, FY25 Q3: 15.5% Revenue growth, TTM YoY, FY25 Q4: 20.2% Revenue growth, TTM YoY, FY26 Q1: 20.5% Revenue growth, TTM YoY, FY26 Q2: 19.5% 19.5%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 6.7%
FY23 Q4 6.0%
FY24 Q1 6.4%
FY24 Q2 6.5%
FY24 Q3 6.2%
FY24 Q4 6.8%
FY25 Q1 9.0%
FY25 Q2 11.5%
FY25 Q3 15.5%
FY25 Q4 20.2%
FY26 Q1 20.5%
FY26 Q2 19.5%
Operating margin (TTM) Aveanna Healthcare Holdings, Inc.
-20% -10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -12.1% Operating margin (TTM), FY23 Q4: 0.4% Operating margin (TTM), FY24 Q1: 0.7% Operating margin (TTM), FY24 Q2: 0.7% Operating margin (TTM), FY24 Q3: 6.2% Operating margin (TTM), FY24 Q4: 6.9% Operating margin (TTM), FY25 Q1: 8.1% Operating margin (TTM), FY25 Q2: 9.7% Operating margin (TTM), FY25 Q3: 10.1% Operating margin (TTM), FY25 Q4: 10.5% Operating margin (TTM), FY26 Q1: 10.9% Operating margin (TTM), FY26 Q2: 10.5% 10.5%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -12.1%
FY23 Q4 0.4%
FY24 Q1 0.7%
FY24 Q2 0.7%
FY24 Q3 6.2%
FY24 Q4 6.9%
FY25 Q1 8.1%
FY25 Q2 9.7%
FY25 Q3 10.1%
FY25 Q4 10.5%
FY26 Q1 10.9%
FY26 Q2 10.5%
FCF margin (TTM) Aveanna Healthcare Holdings, Inc.
-2% 0% 2% 4% 6% 8% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -1.6% FCF margin (TTM), FY23 Q4: 0.5% FCF margin (TTM), FY24 Q1: -0.5% FCF margin (TTM), FY24 Q2: 0.2% FCF margin (TTM), FY24 Q3: 0.2% FCF margin (TTM), FY24 Q4: 1.1% FCF margin (TTM), FY25 Q1: 1.2% FCF margin (TTM), FY25 Q2: 3.5% FCF margin (TTM), FY25 Q3: 3.5% FCF margin (TTM), FY25 Q4: 4.7% FCF margin (TTM), FY26 Q1: 5.1% FCF margin (TTM), FY26 Q2: 6.0% 6.0%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -1.6%
FY23 Q4 0.5%
FY24 Q1 -0.5%
FY24 Q2 0.2%
FY24 Q3 0.2%
FY24 Q4 1.1%
FY25 Q1 1.2%
FY25 Q2 3.5%
FY25 Q3 3.5%
FY25 Q4 4.7%
FY26 Q1 5.1%
FY26 Q2 6.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Aveanna Healthcare Holdings took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $2.4B
  2. Cost of revenue $1.6B · 66.7%
  3. Gross profit $810M · 33.3%
  4. Selling, general and admin $374M · 15.4%
  5. Other operating costs $180M · 7.4%
  6. Operating income $256M · 10.5%
  7. Interest and other $31.4M · 1.3%
  8. Net income $225M · 9.2%

Shares of revenue. Source: Aveanna Healthcare Holdings's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Jan 2021 2021 Jan 2022 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Jan 2026 LTM Jul 2026
Income
Revenue 1,384 1,495 1,679 1,788 1,895 2,025 2,433 2,603
Gross profit 419 455 542 553 595 636 810 840
EBITDA 53 14 −16 −621 22 151 267 285
Operating income 39 −3 −36 −642 8 140 256 274
Net income −77 −57 −117 −662 −135 −11 225 275
Diluted EPS −$0.56 −$0.40 −$0.69 −$3.57 −$0.71 −$0.06 $1.05 $1.23
Growth (year on year)
Revenue — +8.0% +12.3% +6.5% +6.0% +6.8% +20.2% +19.5%
EBITDA — −74.6% — — — — +77.3% +28.5%
Operating income — −109.0% — — — — +83.5% +29.4%
Margins
Gross margin 30.3% 30.4% 32.3% 30.9% 31.4% 31.4% 33.3% 32.3%
EBITDA margin 3.8% 0.9% −0.9% −34.7% 1.2% 7.4% 11.0% 11.0%
Operating margin 2.8% −0.2% −2.2% −35.9% 0.4% 6.9% 10.5% 10.5%
Net margin −5.5% −3.8% −7.0% −37.0% −7.1% −0.5% 9.2% 10.6%
Free-cash-flow margin −1.8% 6.8% −1.6% −2.7% 1.2% 1.6% 5.2% 6.5%
Cash flow
Cash from operations −9 117 −11 −48 23 33 126 168
Capital spending 17 15 16 0 0 0 0 0
Free cash flow −25 101 −27 −48 23 33 126 168
Stock-based pay 2 3 14 16 13 17 25 17
Free cash flow after stock pay −27 98 −42 −64 10 15 101 151
Balance sheet
Cash — 137 30 19 44 84 193 97
Total debt — 1,205 1,273 1,324 1,315 1,306 1,322 1,318
Net debt (negative = net cash) — 1,067 1,242 1,305 1,271 1,221 1,128 1,221
Diluted shares 137m 141m 171m 186m 190m 193m 215m 223m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · July 4, 2026
What it owns · $2.1bn
Short-term assets $478mLonger-term assets $1.6bn
What it owes, and who funded it · $2.1bn
Short-term liabilities $411mLonger-term liabilities $1.4bnShareholders' equity $287m
  • Short-term assets cover short-term liabilities $478m of assets due within a year against $411m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $478m short-term assets against $1.4bn of longer-dated liabilities.
  • More cash than debt $97m of cash against $1.3bn of debt.
  • Debt below 40% of shareholders' equity Debt is 452% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 193% to 452% over five years.
  • A year's operating cash flow covers at least 20% of debt $168m of operating cash flow against $1.3bn of debt.
  • Operating profit covers interest at least five times over Operating income of $274m against $125m of interest.

From Aveanna Healthcare Holdings, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+11.4%
year over year
Sales & admin spending
14.8%
of revenue
Days sales outstanding
47 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated AVAH HIMS CHE PRVA RDNT EVH Median
Revenue, last 12 months $2.6bn $2.6bn $2.7bn $2.4bn $2.3bn $2.1bn $1.2bn
Revenue growth, last 12 months 19.5% 28.0% 5.2% 24.1% 18.9% −4.5% 7.3%
Revenue growth, 3-year average 12.4% 53.7% 6.1% 16.1% 14.1% 8.7% 11.3%
Revenue growth, latest quarter 13.7% 38.2% 10.6% 21.4% 25.0% 46.9% 8.5%
Gross margin 32.3% 68.4% 33.5% — 13.4% 17.2% 27.9%
Operating margin 10.5% −6.0% 13.9% 1.9% 3.1% −20.4% 2.3%
Operating margin, 3-year average 7.0% 0.5% 14.4% 1.2% 4.4% −8.0% 2.3%
Net margin 10.6% −5.5% 10.6% 1.2% −0.9% −24.1% 1.2%
Cash from operations / revenue 6.5% 10.2% 13.6% 5.6% 13.7% 2.6% 6.1%
Free-cash-flow margin 6.0% 2.4% 11.1% 5.6% 3.2% −2.7% 5.1%
Free-cash-flow margin, 3-year average 3.2% — 11.6% 5.2% 3.7% −2.3% 3.6%
Stock pay / revenue 0.7% 6.0% — 3.2% 2.6% 2.0% 1.1%
Change in share count 11.4% 0.3% −8.3% 2.7% 0.1% −2.4% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 19.5% 7.3% 12 of 41
Change in growth rate Growth -1.0pp +1.1pp 31 of 41
Gross margin Profitability 32.3% 29.0% 13 of 27
Operating margin Profitability 10.5% 2.6% 8 of 40
Net margin Profitability 10.6% 1.2% 6 of 41
Free-cash-flow margin Cash generation 6.0% 5.1% 16 of 40
Stock pay as % of revenue Cash generation 0.7% 0.9% 8 of 35
Long-term debt as % of assets Balance sheet 61.0% 27.7% 29 of 31
Change in share count Balance sheet 11.4% 0.4% 33 of 39
Days sales outstanding Balance sheet 47 days 39 days 22 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to January 3, 2026
Segments
Line of business Revenue Share YoY
Private Duty Services $2B 82.2% ▲ 22.4%
Home Health and Hospice $249M 10.2% ▲ 14.1%
Medical Solutions $183M 7.5% ▲ 6.6%

From Aveanna Healthcare Holdings, Inc.'s 10-K filed March 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.7B
Institutions reporting
213
Shares held vs prior quarter
▲ 2.6%
Positions opened / closed
53 / 32

Top buyers and sellers, Q2 2026: 149 institutions bought and 82 sold ; the biggest buyer was Ophir Asset Management Pty Ltd (+5.1M shares) and the biggest seller J.H. Whitney Equity Partners Vii, LLC (−9.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Bain Capital Investors LLC $699M 81.6M 40.2% 0.0%
J.H. Whitney Equity Partners Vii, LLC $232M 27.1M 13.3% ▼ 25.3%
Nut Tree Capital Management, LP $111M 12.9M 6.4% 0.0%
Blackrock, Inc. $63.5M 7.4M 3.7% ▲ 34.7%
Ophir Asset Management Pty Ltd $43.7M 5.1M 2.5% New
Vanguard Capital Management LLC $31.5M 3.7M 1.8% ▼ 7.6%
Braidwell LP $26.3M 3.1M 1.5% ▲ 39.1%
Boston Partners $24.9M 2.9M 1.4% ▲ 1.7%
Citadel Advisors LLC $19.6M 2.3M 1.1% ▲ 725.3%
Dimensional Fund Advisors LP $19.3M 2.3M 1.1% ▲ 69.2%
Mackenzie Financial Corp $18.1M 2.1M 1.0% ▲ 302.8%
Geode Capital Management, LLC $17.7M 2.1M 1.0% ▲ 20.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Aveanna Healthcare Holdings, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $782M 71 trades by 9 insiders · 1% under pre-set plans
Net ▼ $782M net selling
Insider Date Trade Shares Price Value
Vigano Paul R 10% owner August 21, 2026 Sell 2,250,000 $11.50 $25.9M
Williams Robert M Jr 10% owner August 21, 2026 Sell 2,250,000 $11.50 $25.9M
J.H. Whitney Equity Partners Vii, Llc 10% owner August 21, 2026 Sell 2,250,000 $11.50 $25.9M
Reisz Edwin C. Chief Administrative Officer August 20, 2026 Sell 50,000 $11.50 $575,000
Shaner Jeff Chief Executive Officer August 20, 2026 Sell 90,000 $11.50 $1M
Windley Rodney D Director August 20, 2026 Sell 180,000 $11.50 $2.1M
Vigano Paul R 10% owner August 20, 2026 Sell 10,112,125 $11.50 $116M
Vigano Paul R 10% owner August 20, 2026 Sell 957,918 $11.50 $11M
Vigano Paul R 10% owner August 20, 2026 Sell 1,813,795 $11.50 $20.9M
Vigano Paul R 10% owner August 20, 2026 Sell 1,426,034 $11.50 $16.4M
Vigano Paul R 10% owner August 20, 2026 Sell 190,130 $11.50 $2.2M
Williams Robert M Jr 10% owner August 20, 2026 Sell 957,918 $11.50 $11M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 13, 2026
  • May 14, 2026
  • March 19, 2026
  • January 14, 2026
  • November 6, 2025
  • October 21, 2025

Recent SEC filings

Data status

When each part of this page on Aveanna Healthcare Holdings, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Aveanna Healthcare Holdings, Inc. in brief

What does Aveanna Healthcare Holdings, Inc. do?
Aveanna Healthcare Holdings, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Aveanna Healthcare Holdings, Inc.'s stock ticker?
Aveanna Healthcare Holdings, Inc. trades under the ticker AVAH on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Aveanna Healthcare Holdings, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Aveanna Healthcare Holdings, Inc. reported revenue of $2.6B, 19.5% higher than a year earlier, according to its SEC filings.
What is Aveanna Healthcare Holdings, Inc.'s free cash flow?
Aveanna Healthcare Holdings, Inc.'s free-cash-flow margin is 6.0% of revenue over the trailing twelve months, ranking 16 of the 40 health care services companies we cover.
Who are Aveanna Healthcare Holdings, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Bain Capital Investors LLC, J.H. Whitney Equity Partners Vii, LLC and Nut Tree Capital Management, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Aveanna Healthcare Holdings, Inc.'s market cap?
On November 2, 2026, Aveanna Healthcare Holdings, Inc.'s market capitalisation was about $2.9B, with a price-to-earnings ratio of 10.6 and net debt of $1.2B. Market figures come from third-party market data and may be delayed.
How much debt does Aveanna Healthcare Holdings, Inc. have?
Aveanna Healthcare Holdings, Inc.'s debt-to-equity ratio is 451.8%, from its latest balance sheet (192.9% five years earlier). The financial health section below sets out its other solvency checks.
Who are Aveanna Healthcare Holdings, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Aveanna Healthcare Holdings, Inc. are Hims & Hers Health, Inc., Chemed Corp, Privia Health Group, Inc., Radnet, Inc. and Evolent Health, Inc. The side-by-side comparison below sets their revenue, margins and growth against Aveanna Healthcare Holdings, Inc.'s.
Are insiders buying or selling Aveanna Healthcare Holdings, Inc. stock?
Over the last 12 months, Aveanna Healthcare Holdings, Inc.'s directors and officers reported 0 open-market purchases and 71 sales on Form 4. The insider trading page charts every trade.
When is Aveanna Healthcare Holdings, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Aveanna Healthcare Holdings, Inc. announces its own schedule.